PDCD1 and glioblastoma: Though the efficacy of the PD-1/PD-L1 blockade therapy is yet somewhat controversial in the clinical management of GBM, it still has shown an overall reduction in the tumor burden combined with the activation of local and systemic immune responses suppressed by the tumor microenvironment (19, 20).